Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Emergency Preparedness and Response

MCMi FY 2013: Medical Countermeasure Resources

FDA MCMi Fiscal Year 2013 Program Update

Previous section: Background

Medical Countermeasure Resources

FDA obligated $169.5 million in FY 2013 to support CBRN and pandemic influenza-related medical countermeasure activities (Table 1). These resources comprised a combination of base funding and no-year funding.


Table 1: FY 2013 Resources Obligated to Medical Countermeasure Activities (dollars in millions)
  FY 13 ActualsFY 13 FTE Actuals
 CBRN Base Funding $62.3 317
 Pandemic Influenza Base Funding $32.1 158
 MCMi Base Funding $21.8 77
 No-Year Funding $53.3 8
 Total $169.5 560

Base Funding 

FDA obligated $116.2 million from its FY 2013 base resources to support CBRN and pandemic influenza-related medical countermeasure activities. This funding included $62.3 million for CBRN preparedness activities, $32.1 million for pandemic influenza preparedness activities, and $21.8 million for the MCMi.  (10)

This funding supported 452 FTEs as well as a $0.9 million investment in the MCMi regulatory science program. 

No-Year Funding

FDA received $170 million, one-time funding from HHS to immediately commence MCMi activities at the end of FY 2010 when the MCMi was launched. In FY 2013, FDA obligated $53.3 million of the no-year funding to support MCMi activities. (11)  This funding supported 8 FTEs as well as regulatory science projects and infrastructure for the MCMi Regulatory Science Program and other non-payroll MCMi costs (e.g., professional development).


(10) In FY 2013, Congress provided FDA with $23.5 million base funding for the MCMi, however, as a result of reductions experienced with the sequester and rescission in FY 2013, the total estimated FY 2013 MCMi budget authority is $21.8 million.

(11) FDA expended $49.9 million of the $170 million no-year funding during FY 2011, and $54.6 million during FY 2012. FDA anticipates expending the remaining balance of the no-year funding (approximately $12.2 million) through FY 2015. 

Next section: FY 2013 Objectives, Activities, and Achievements

Back to Table of Contents

Page Last Updated: 06/30/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English